Yusuke Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yusuke Sato has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Hiroshi Tada
Division of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
7 shared publicationsHiroyasu Uzui
Division of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
6 shared publicationsTetsuji Morishita
Internal Medicine, Matsunami General Hospital, Gifu, Japan
5 shared publicationsKazushi Urasawa
Cardiovascular Center Tokeidai Memorial Hospital
4 shared publicationsTomohiro Shimizu
Division of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
4 shared publicationsHiroyuki Ikeda
Division of Cardiovascular Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan
3 shared publications
Latest Publications
- 31 March 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (4) , 505-516
Impact of lipid-rich plaques in the femoropopliteal artery on limb outcomes in patients undergoing endovascular therapy
Background: The impact of lipid-rich plaques (LRPs) in the femoropopliteal artery on limb outcomes remains underexplored. We investigated the influence of LRPs on limb outcomes in patients undergoing endovascular therapy (EVT) for femoropopliteal disease. Methods: This single-center, prospective noninterventional observational study included patients undergoing drug-coated balloon angioplasty for femoropopliteal disease between July 2022 and November 2024. Near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) assessment was conducted on the entire femoropopliteal arterial segment. LRP was defined as plaque with a maximum lipid-core burden index in any 4-mm region > 400. The primary outcome was major adverse limb events (MALEs) at 12 months. Secondary outcomes included primary patency and target-vessel revascularization (TVR) at 12 months. TVR was defined as any repeat EVT or surgical bypass of any segment of the target vessel. Results: Fifty participants were divided into LRP ( n = 19) and non-LRP ( n = 31) groups. The LRP group had significantly lower freedom from MALE at 12 months compared with the non-LRP group (69.1%, 95% CI: 35.7–87.6 vs 92.3%, 95% CI: 72.1–98.0, log-rank p = 0.01). LRP was associated with poorer freedom from MALE at 12 months (hazard ratio [HR]: 6.3, 95% CI: 1.3–38.8, p = 0.02). Both groups showed comparable primary patency and freedom from TVR at 12 months (log-rank p = 0.03 for both). LRP was associated with lower primary patency (HR: 5.1, 95% CI: 0.97–26.7, p = 0.054) and lower freedom from TVR (HR: 5.3, 95% CI: 1.01–27.8, p = 0.049) at 12 months. Conclusion: LRPs were associated with poor 12-month limb outcomes in patients undergoing EVT for femoropopliteal disease. University Hospital Medical Information Network (UMIN) Clinical Trials Registry ID: UMIN000049231 .
- 31 March 2026
- Published by SAGE Publications in Vascular Medicine
- Vol. 31 (4) , 505-516
Impact of lipid-rich plaques in the femoropopliteal artery on limb outcomes in patients undergoing endovascular therapy
Background: The impact of lipid-rich plaques (LRPs) in the femoropopliteal artery on limb outcomes remains underexplored. We investigated the influence of LRPs on limb outcomes in patients undergoing endovascular therapy (EVT) for femoropopliteal disease. Methods: This single-center, prospective noninterventional observational study included patients undergoing drug-coated balloon angioplasty for femoropopliteal disease between July 2022 and November 2024. Near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) assessment was conducted on the entire femoropopliteal arterial segment. LRP was defined as plaque with a maximum lipid-core burden index in any 4-mm region > 400. The primary outcome was major adverse limb events (MALEs) at 12 months. Secondary outcomes included primary patency and target-vessel revascularization (TVR) at 12 months. TVR was defined as any repeat EVT or surgical bypass of any segment of the target vessel. Results: Fifty participants were divided into LRP ( n = 19) and non-LRP ( n = 31) groups. The LRP group had significantly lower freedom from MALE at 12 months compared with the non-LRP group (69.1%, 95% CI: 35.7–87.6 vs 92.3%, 95% CI: 72.1–98.0, log-rank p = 0.01). LRP was associated with poorer freedom from MALE at 12 months (hazard ratio [HR]: 6.3, 95% CI: 1.3–38.8, p = 0.02). Both groups showed comparable primary patency and freedom from TVR at 12 months (log-rank p = 0.03 for both). LRP was associated with lower primary patency (HR: 5.1, 95% CI: 0.97–26.7, p = 0.054) and lower freedom from TVR (HR: 5.3, 95% CI: 1.01–27.8, p = 0.049) at 12 months. Conclusion: LRPs were associated with poor 12-month limb outcomes in patients undergoing EVT for femoropopliteal disease. University Hospital Medical Information Network (UMIN) Clinical Trials Registry ID: UMIN000049231 .
- 23 March 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 40 (3) , 715-716
Proximal SFA CTO puncture for femoropopliteal occlusive disease
- 23 March 2025
- Published by Springer Nature in Cardiovascular Intervention and Therapeutics
- Vol. 40 (3) , 715-716
Proximal SFA CTO puncture for femoropopliteal occlusive disease
- 24 December 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (3) , 698-706
Impact of Below‐the‐Knee Runoff in Patients With Lower Extremity Artery Disease Who Underwent Endovascular Therapy Using Drug‐Coated Balloons in Femoropopliteal Lesions
Background: The impact of below‐the‐knee (BK) runoff after drug‐coated balloon (DCB) treatment in femoropopliteal (FP) lesions has not been well investigated.Methods: This retrospective multicenter observational study enrolled 291 consecutive patients with lower extremity artery disease who underwent endovascular therapy with DCBs for FP lesions between January 2018 and December 2021. Patients were classified into four groups based on the BK runoff. Outcome measures included primary patency, freedom from clinically driven target lesion revascularization (CD‐TLR) and amputation, and overall survival rates at 24 months. The predictors of restenosis at 24 months were also investigated.Results: In total, 43, 98, 117, and 33 patients were classified into three, two, one, and no BK runoff groups, respectively. In three, two, one, and no BK runoff groups, the primary patency rates were 72.1%, 67.3%, 61.4%, and 44.1% (p = 0.028); freedom from CD‐TLR rates were 87.1%, 78.8%, 71.7%, and 47.1% (p < 0.001); freedom from amputation rates were 95.2%, 97.9%, 92.8%, and 91.5% (p = 0.499); and overall survival rates were 89.4%, 83.2%, 76.6%, and 61.2% (p = 0.007), respectively, at 24 months. Multivariate analysis showed that chronic limb‐threatening ischemia, no BK runoff, Lutonix use, and residual stenosis > 30% were independent predictors of primary patency loss at 24 months. The risk score, calculated as the number of predictors, reflected the risk of restenosis.Conclusion: No BK runoff was associated with worse midterm primary patency, freedom from CD‐TLR, and overall survival rates than at least one BK runoff.
- 24 December 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 105 (3) , 698-706
Impact of Below‐the‐Knee Runoff in Patients With Lower Extremity Artery Disease Who Underwent Endovascular Therapy Using Drug‐Coated Balloons in Femoropopliteal Lesions
Background: The impact of below‐the‐knee (BK) runoff after drug‐coated balloon (DCB) treatment in femoropopliteal (FP) lesions has not been well investigated.Methods: This retrospective multicenter observational study enrolled 291 consecutive patients with lower extremity artery disease who underwent endovascular therapy with DCBs for FP lesions between January 2018 and December 2021. Patients were classified into four groups based on the BK runoff. Outcome measures included primary patency, freedom from clinically driven target lesion revascularization (CD‐TLR) and amputation, and overall survival rates at 24 months. The predictors of restenosis at 24 months were also investigated.Results: In total, 43, 98, 117, and 33 patients were classified into three, two, one, and no BK runoff groups, respectively. In three, two, one, and no BK runoff groups, the primary patency rates were 72.1%, 67.3%, 61.4%, and 44.1% (p = 0.028); freedom from CD‐TLR rates were 87.1%, 78.8%, 71.7%, and 47.1% (p < 0.001); freedom from amputation rates were 95.2%, 97.9%, 92.8%, and 91.5% (p = 0.499); and overall survival rates were 89.4%, 83.2%, 76.6%, and 61.2% (p = 0.007), respectively, at 24 months. Multivariate analysis showed that chronic limb‐threatening ischemia, no BK runoff, Lutonix use, and residual stenosis > 30% were independent predictors of primary patency loss at 24 months. The risk score, calculated as the number of predictors, reflected the risk of restenosis.Conclusion: No BK runoff was associated with worse midterm primary patency, freedom from CD‐TLR, and overall survival rates than at least one BK runoff.
- Open Access
- 24 July 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (3) , 540-547
Evaluation of nontarget lesions in femoropopliteal disease using near‐infrared spectroscopy intravascular ultrasound imaging
Background: In coronary artery disease (CAD), lipid‐core‐containing plaque (LCP) in nontarget lesions detected using near‐infrared spectroscopy intravascular ultrasound (NIRS‐IVUS) was related to increased major adverse cardiovascular events in patients with CAD. In the endovascular therapy field, few previous studies using NIRS‐IVUS revealed the presence of LCPs in severe stenotic lesions of femoropopliteal disease.Aim: This study aimed to assess the plaque morphology of nontarget lesions, especially LCPs, and compare it with that of target lesions using NIRS‐IVUS in patients with femoropopliteal disease.Methods: This single‐center prospective observational study included 14 patients who underwent endovascular therapy for FP disease. NIRS‐IVUS assessment was performed on the entire FP arterial segment. Forty‐one LCP lesions with a maximum lipid‐core burden index in any 4‐mm region (max LCBI4mm) > 100 were detected using NIRS‐IVUS. We evaluated the patient and lesion characteristics. LCP lesions were divided into the target (n = 18) and nontarget (n = 23) lesion groups for comparison.Results: Patient characteristics were notable for advanced age (76.8 ± 6.6 years); high proportion of males (78.7%); and high incidence of hypertension (100%), dyslipidemia (78.6%), diabetes (64.3%). Regarding NIRS findings, the target lesion group exhibited a significantly smaller proportion of LCPs concerning the lesion length (25.9 ± 15.7% vs. 50.6 ± 29.2%, p = 0.002) than the nontarget lesion group. Conversely, there were no significant differences in the value of max LCBI4mm (284.4 ± 153.4 vs. 289.5 ± 113.1, p = 0.90), length of LCP lesion (9.8 ± 9.7 mm vs. 10.7 ± 6.9 mm, p = 0.74), and distribution of LCPs (p = 0.08) between the groups. In addition, the number of LCPs in the target FP artery positively correlated with max LCBI4mm in the target FP artery (r = 0.671, p = 0.008).Conclusions: NIRS‐IVUS findings demonstrated the presence of LCPs in nontarget lesions in patients with FP disease. Moreover, the abundance of LCPs in nontarget lesions was similar to that in target lesions in FP disease.
- 24 July 2024
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 104 (3) , 540-547
Open AccessEvaluation of nontarget lesions in femoropopliteal disease using near‐infrared spectroscopy intravascular ultrasound imaging
Background: In coronary artery disease (CAD), lipid‐core‐containing plaque (LCP) in nontarget lesions detected using near‐infrared spectroscopy intravascular ultrasound (NIRS‐IVUS) was related to increased major adverse cardiovascular events in patients with CAD. In the endovascular therapy field, few previous studies using NIRS‐IVUS revealed the presence of LCPs in severe stenotic lesions of femoropopliteal disease.Aim: This study aimed to assess the plaque morphology of nontarget lesions, especially LCPs, and compare it with that of target lesions using NIRS‐IVUS in patients with femoropopliteal disease.Methods: This single‐center prospective observational study included 14 patients who underwent endovascular therapy for FP disease. NIRS‐IVUS assessment was performed on the entire FP arterial segment. Forty‐one LCP lesions with a maximum lipid‐core burden index in any 4‐mm region (max LCBI4mm) > 100 were detected using NIRS‐IVUS. We evaluated the patient and lesion characteristics. LCP lesions were divided into the target (n = 18) and nontarget (n = 23) lesion groups for comparison.Results: Patient characteristics were notable for advanced age (76.8 ± 6.6 years); high proportion of males (78.7%); and high incidence of hypertension (100%), dyslipidemia (78.6%), diabetes (64.3%). Regarding NIRS findings, the target lesion group exhibited a significantly smaller proportion of LCPs concerning the lesion length (25.9 ± 15.7% vs. 50.6 ± 29.2%, p = 0.002) than the nontarget lesion group. Conversely, there were no significant differences in the value of max LCBI4mm (284.4 ± 153.4 vs. 289.5 ± 113.1, p = 0.90), length of LCP lesion (9.8 ± 9.7 mm vs. 10.7 ± 6.9 mm, p = 0.74), and distribution of LCPs (p = 0.08) between the groups. In addition, the number of LCPs in the target FP artery positively correlated with max LCBI4mm in the target FP artery (r = 0.671, p = 0.008).Conclusions: NIRS‐IVUS findings demonstrated the presence of LCPs in nontarget lesions in patients with FP disease. Moreover, the abundance of LCPs in nontarget lesions was similar to that in target lesions in FP disease.
- Open Access
- 26 September 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (6) , 3573-3581
Effects of Door-to-Tolvaptan Time on Short-Term Clinical Outcome in Patients with Acute Heart Failure
Aims: We investigated the effects of door-to-tolvaptan (D2T) time on short-term urine volume and in-hospital clinical outcomes in patients with acute heart failure (AHF). Methods and results: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the ‘early group’. The primary outcome was 48-h urine volume. The secondary outcomes were in-hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48-h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0–31.9 h). Seventy-four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In-hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01). Conclusions: The shorter D2T time did not affect the short-term urine volume and in-hospital outcomes but reduced the risk of WRF incidence in patients with AHF.
- 26 September 2023
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 10 (6) , 3573-3581
Open AccessEffects of Door-to-Tolvaptan Time on Short-Term Clinical Outcome in Patients with Acute Heart Failure
Aims: We investigated the effects of door-to-tolvaptan (D2T) time on short-term urine volume and in-hospital clinical outcomes in patients with acute heart failure (AHF). Methods and results: Patients with AHF, treated with tolvaptan at two hospitals, were enrolled in this retrospective observational study. The D2T time was defined as the time elapsed from the arrival of a patient at a participating hospital to the first administration of tolvaptan. The group with the D2T time within 6 h was defined as the ‘early group’. The primary outcome was 48-h urine volume. The secondary outcomes were in-hospital death, length of hospital stay, and worsening renal function (WRF) incidence. A restricted cubic spline model was used to evaluate the presence of a nonlinear association between the D2T time and 48-h urine volume and the odds ratio of WRF incidence. Our study included a total of 138 patients with AHF who were started on tolvaptan after hospitalization. The median D2T time was 5.3 h (interquartile range: 3.0–31.9 h). Seventy-four patients (53.6%) were classified to be in the early group. Baseline characteristics were similar in the two groups: mean age (85.4 ± 9.6 years vs. 84.5 ± 9.5 years; P = 0.59) and male sex (n = 22 [33.3%] vs. n = 29 [46%]; P = 0.16), except that patients in the early group had higher systolic blood pressure than those in the delayed group (138.2 ± 22.9 vs. 125.7 ± 21.7; P = 0.001). The initial tolvaptan dose in the delayed group was much lower than that in the early group (7.5 [7.5, 7.5] vs. 7.5 [5.6, 7.5] mg; P = 0.01). Total urine volume in 48 h did not differ in the early and delayed groups (4113 ± 1758 mL vs. 4201 ± 1893 mL; P = 0.80). The relationship between D2T time and total urine volume within 48 h increased slightly, with a peak at a D2T time of 15 h, and gradually decreased, thereafter. In-hospital death and the length of hospital stay did not differ significantly between the two groups (n = 1, 1.3% vs. n = 4, 6.3%; P = 0.18, and 5.0 [12.0, 30.0] vs. 22.0 [14.5, 30.0] days; P = 0.17, respectively). Notably, the restricted cubic spline model for the odds ratio of WRF incidence increased as the D2T time was delayed (P for effect<0.01). Conclusions: The shorter D2T time did not affect the short-term urine volume and in-hospital outcomes but reduced the risk of WRF incidence in patients with AHF.
- Open Access
- 23 June 2023
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 87 (7) , 1034
Angioscopy Using CO2 for Femoropopliteal Occlusive Disease
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 23 June 2023
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 87 (7) , 1034
Open AccessAngioscopy Using CO2 for Femoropopliteal Occlusive Disease
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 10 November 2022
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 4 (11) , 557-558
Stent Size Reduction Phenomenon in Optical Frequency Domain Imaging Using CO2
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 10 November 2022
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 4 (11) , 557-558
Open AccessStent Size Reduction Phenomenon in Optical Frequency Domain Imaging Using CO2
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 8 April 2022
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 63 (6) , 852-863
Prediction of Technical Failure of Inframalleolar Angioplasty in Patients with Chronic Limb Threatening Ischaemia
- 8 April 2022
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 63 (6) , 852-863
Prediction of Technical Failure of Inframalleolar Angioplasty in Patients with Chronic Limb Threatening Ischaemia
- 3 January 2022
- Published by SAGE Publications in Vascular
- Vol. 31 (2) , 325-332
A novel endovascular method of atherectomy for calcified common femoral and popliteal disease using the crosser system: Crossbow and Rambow techniques
Objectives: This study aims to report the efficacy and safety of new atherectomy methods using the Crosser system for calcified lesions in the common femoral and popliteal artery: the Crosser system supported by bended 0.014 wire (Crossbow) technique and retrograde approach of sheathless Crosser system supported by bended 0.014 wire (Rambow) technique. Materials and Methods: This report describes a single-center, retrospective study. A total of 23 patients (mean ± SD age, 73 ± 10 years; 19 men) with symptomatic peripheral artery disease received the Crossbow technique and Rambow technique for treatment of calcified common femoral and popliteal disease; these patients were enrolled between October 2013 and October 2015. The primary efficacy outcome was acute technical success, defined as achievement of residual stenosis < 30% for stenting and < 50% for angioplasty or atherectomy. The primary safety outcome was assessed on the basis of angiographic complications. Results: The Crossbow and Rambow techniques were undertaken in 100% and 17% of the patients, respectively. Acute technical success was achieved in 96% of the patients. There were two embolic events. Conclusion: Crossbow and Rambow techniques could be effective atherectomy methods of calcified common femoral and popliteal disease. Regarding safety, embolic protection devices may be needed for our atherectomy methods.
- 3 January 2022
- Published by SAGE Publications in Vascular
- Vol. 31 (2) , 325-332
A novel endovascular method of atherectomy for calcified common femoral and popliteal disease using the crosser system: Crossbow and Rambow techniques
Objectives: This study aims to report the efficacy and safety of new atherectomy methods using the Crosser system for calcified lesions in the common femoral and popliteal artery: the Crosser system supported by bended 0.014 wire (Crossbow) technique and retrograde approach of sheathless Crosser system supported by bended 0.014 wire (Rambow) technique. Materials and Methods: This report describes a single-center, retrospective study. A total of 23 patients (mean ± SD age, 73 ± 10 years; 19 men) with symptomatic peripheral artery disease received the Crossbow technique and Rambow technique for treatment of calcified common femoral and popliteal disease; these patients were enrolled between October 2013 and October 2015. The primary efficacy outcome was acute technical success, defined as achievement of residual stenosis < 30% for stenting and < 50% for angioplasty or atherectomy. The primary safety outcome was assessed on the basis of angiographic complications. Results: The Crossbow and Rambow techniques were undertaken in 100% and 17% of the patients, respectively. Acute technical success was achieved in 96% of the patients. There were two embolic events. Conclusion: Crossbow and Rambow techniques could be effective atherectomy methods of calcified common femoral and popliteal disease. Regarding safety, embolic protection devices may be needed for our atherectomy methods.